Altimmune to Present Pemvidutide Clinical Data at ADA Scientific Sessions

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced that it will present its investigational drug, pemvidutide, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. The event will take place in Orlando, Florida, from June 21-24, 2024. Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed for treating obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Two key oral presentations will be delivered during the ADA sessions. The first presentation, titled "Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids," will be presented by Dr. John J. Suschak, Senior Director of Translational Science at Altimmune. This presentation is scheduled for Saturday, June 22, 2024, at 4:45 pm EDT, as part of the session "Leveling Up Incretin-Based Therapy in Type 2 Diabetes," which runs from 4:30 PM to 6:00 PM.

The second presentation, titled "Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity – A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial," will be presented by Dr. Louis Aronne, Professor of Metabolic Research and Clinical Medicine at Weil Cornell Medical School. This will be part of the session "Weighing Opportunities of Incretin-Based Therapy in Obesity," scheduled for Sunday, June 23, 2024, from 1:30 pm to 3:00 pm. Dr. Aronne’s presentation is set for 1:45 pm EDT and will also be featured in the ADA's official Press Program.

Pemvidutide is an innovative peptide-based GLP-1/glucagon dual receptor agonist designed to treat obesity and MASH. The GLP-1 receptor activation helps suppress appetite while the glucagon receptor activation boosts energy expenditure. Additionally, glucagon's direct effect on liver fat metabolism can lead to significant reductions in liver fat and serum lipids. Clinical trials of pemvidutide have shown notable weight loss, and reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for MASH treatment. The drug recently completed the MOMENTUM Phase 2 obesity trial and is currently being studied in the ongoing IMPACT Phase 2b MASH trial.

Altimmune is a forward-looking biopharmaceutical company focused on developing next-generation peptide-based therapeutics. The company's current focus includes advancing pemvidutide for obesity and MASH treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!